

Correction

Correction: Interleukin-6: a new therapeutic target

Josef S Smolen¹ and Ravinder N Maini²

¹Professor of Medicine, Chairman Division of Rheumatology, Medical University of Vienna, Vienna, Austria

²Emeritus Professor of Rheumatology, The Kennedy Institute of Rheumatology Division, Imperial College, London, UK

Published: 17 October 2006

This article is online at <http://arthritis-research.com/content/8/6/407>

© 2006 BioMed Central Ltd

Arthritis Research & Therapy 2006, **8**:407 (doi:10.1186/ar2065)

Following the publication of the above article [1], we noticed that due to an administrative oversight the Competing interests section was incomplete and should read as follows:

JSS has received financial compensation from and served on advisory boards for Roche and is an investigator in clinical trials of tocilizumab. RNM has received consulting fees from Chugai; served on an ad hoc advisory board for Roche; and was responsible for the planning and preparation for publication of the Phase II European (CHARISMA) trial of tocilizumab with and without methotrexate. A patent for co-administration of methotrexate and tocilizumab for the treatment of rheumatoid arthritis, of which RNM is named as a co-inventor, has been applied for and fully assigned to Chugai.

Reference

1. Smolen JS, Maini RN: **Interleukin-6: a new therapeutic target.** *Arthritis Res Ther* 2006, **8** (Suppl 2):S5.